Moberg Pharma AB (publ) (MOB.ST)

26.42 -1.62 (-5.78%) At close: 05:29PM CEST

Moberg Pharma AB (publ)

GustavslundsvAegen 42
5th Floor
Bromma 167 51
Sweden
46 8 52 23 07 00
https://www.mobergpharma.se

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Anna Ljung BA, M.Sc.	Chief Executive Officer	2.93M	N/A	1980
Ms. Marie Moberg	Co-Founder	193.7k	N/A	N/A
Mr. Mark Beveridge	Vice President of Finance	N/A	N/A	1978
Dr. Christina Erixon	Head of Pharmaceutical Development & Operations	N/A	N/A	1970
Gunilla Wengström	Senior Director of Sales & Marketing	N/A	N/A	N/A
Anders Broijersen M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1964
Mr. Robert Ehrl	Head of Supply	N/A	N/A	1967

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. The company develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

Corporate governance

Moberg Pharma AB (publ)’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.